ライブラリ登録: Guest
Critical Reviews™ in Therapeutic Drug Carrier Systems

年間 6 号発行

ISSN 印刷: 0743-4863

ISSN オンライン: 2162-660X

The Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two preceding years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) IF: 2.7 To calculate the five year Impact Factor, citations are counted in 2017 to the previous five years and divided by the source items published in the previous five years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) 5-Year IF: 3.6 The Immediacy Index is the average number of times an article is cited in the year it is published. The journal Immediacy Index indicates how quickly articles in a journal are cited. Immediacy Index: 0.8 The Eigenfactor score, developed by Jevin West and Carl Bergstrom at the University of Washington, is a rating of the total importance of a scientific journal. Journals are rated according to the number of incoming citations, with citations from highly ranked journals weighted to make a larger contribution to the eigenfactor than those from poorly ranked journals. Eigenfactor: 0.00023 The Journal Citation Indicator (JCI) is a single measurement of the field-normalized citation impact of journals in the Web of Science Core Collection across disciplines. The key words here are that the metric is normalized and cross-disciplinary. JCI: 0.39 SJR: 0.42 SNIP: 0.89 CiteScore™:: 5.5 H-Index: 79

Indexed in

Strategies and Therapeutic Opportunities for the Delivery of Drugs to the Esophagus

巻 25, 発行 3, 2008, pp. 259-304
DOI: 10.1615/CritRevTherDrugCarrierSyst.v25.i3.20
Get accessGet access

要約

Targeting of drugs and therapies locally to the esophagus is an important objective in the development of new and more effective dosage forms. Therapies that are retained within the oral cavity for both local and systemic action have been utilized for many years, although delivery to the esophagus has been far less reported. Esophageal disease states, including infections, motility disorders, gastric reflux, and cancers, would all benefit from localized drug delivery. Therefore, research in this area provides significant opportunities. The key limitation to effective drug delivery within the esophagus is sufficient retention at this site coupled with activity profiles to correspond with these retention times; therefore, a suitable formulation needs to provide the drug in a ready-to-work form at the site of action during the rapid transit through this organ. A successfully designed esophageal-targeted system can overcome these obstacles. This review presents a range of dosage form approaches for targeting the esophagus, including bioadhesive liquids and orally retained lozenges, chewing gums, gels, and films, as well as endoscopically delivered therapeutics. The techniques used to measure efficacy both in vitro and in vivo are also discussed.
Drug delivery is a growing driver within the pharmaceutical industry and offers benefits both in terms of clinical efficacy, as well as in market positioning, as a means of extending a drug's exclusivity and profitability. Emerging systems that can be used to target the esophagus are reported within this review, as well as the potential of alternative formulations that offer benefits in this exciting area.

によって引用された
  1. Grover Liam M., Smith Alan M., Hydrocolloids and Medicinal Chemistry Applications, in Handbook of Biopolymers and Biodegradable Plastics, 2013. Crossref

  2. Grover Liam M., Smith Alan M., Hydrocolloids and Medicinal Chemistry Applications, in Modern Biopolymer Science, 2009. Crossref

  3. Desai Kashappa-Goud H., Mallery Susan R., Holpuch Andrew S., Schwendeman Steven P., Development and In Vitro-In Vivo Evaluation of Fenretinide-Loaded Oral Mucoadhesive Patches for Site-Specific Chemoprevention of Oral Cancer, Pharmaceutical Research, 28, 10, 2011. Crossref

  4. Pinto João F., Site-specific drug delivery systems within the gastro-intestinal tract: From the mouth to the colon, International Journal of Pharmaceutics, 395, 1-2, 2010. Crossref

  5. Fox Cade B., Kim Jean, Le Long V., Nemeth Cameron L., Chirra Hariharasudhan D., Desai Tejal A., Micro/nanofabricated platforms for oral drug delivery, Journal of Controlled Release, 219, 2015. Crossref

  6. Mau Musharrat Mustaree, Sarker Sunandita, Terry Benjamin S, Ingestible devices for long-term gastrointestinal residency: a review, Progress in Biomedical Engineering, 3, 4, 2021. Crossref

  7. Mai Yang, Ouyang Yaqi, Qin Yujia, Jia Changchang, McCoubrey Laura E., Basit Abdul W., Nie Yichu, Jia Yizhen, Yu Liu, Dou Liu, Deng Wenbin, Deng Yang, Liu Yang, Poly(lactic acid)-hyperbranched polyglycerol nanoparticles enhance bioadhesive treatment of esophageal disease and reduce systemic drug exposure, Nanoscale, 14, 23, 2022. Crossref

  8. Franco-de la Torre Lorenzo, Gómez-Sánchez Eduardo, Serafín-Higuera Nicolás Addiel, Alonso-Castro Ángel Josabad, López-Verdín Sandra, Molina-Frechero Nelly, Granados-Soto Vinicio, Isiordia-Espinoza Mario Alberto, Dexamethasone Increases the Anesthetic Success in Patients with Symptomatic Irreversible Pulpitis: A Meta-Analysis, Pharmaceuticals, 15, 7, 2022. Crossref

Begell Digital Portal Begellデジタルライブラリー 電子書籍 ジャーナル 参考文献と会報 リサーチ集 価格及び購読のポリシー Begell House 連絡先 Language English 中文 Русский Português German French Spain